Olectan Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan blocks angiotensin II receptors, preventing vasoconstriction. Amlodipine relaxes arterial smooth muscle by inhibiting calcium entry, causing dilation. Hydrochlorothiazide increases urine output by reducing sodium reabsorption in the kidney, lowering blood volume. Together they produce a synergistic reduction in blood pressure.

The specific dose of Olectan Hct is determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health status, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Olectan Hct is generally not recommended for use during pregnancy because the safety of the combination has not been established. Breastfeeding mothers should consult their healthcare provider, as the drugs may be excreted in milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional verification before supplying pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, Olectan Hct offers three complementary mechanisms in one tablet, which can improve blood‑pressure control and simplify dosing. It may be preferred over separate pills when patients need both an ARB, a calcium‑channel blocker and a thiazide diuretic, reducing pill burden and improving adherence.

Olectan Hct tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include severe hypotension, acute kidney injury, significant electrolyte disturbances (especially low potassium or high sodium), and rare cases of angioedema. Patients should report sudden dizziness, swelling of the face or lips, or marked changes in urine output to their doctor promptly.

Olectan Hct should be avoided in patients with known hypersensitivity to any of its components, severe renal or hepatic impairment, uncontrolled heart failure, or those who are pregnant. Individuals with a history of angioedema or severe electrolyte abnormalities should also discuss alternative therapies with their clinician.